JP2023539949A5 - - Google Patents

Info

Publication number
JP2023539949A5
JP2023539949A5 JP2023537444A JP2023537444A JP2023539949A5 JP 2023539949 A5 JP2023539949 A5 JP 2023539949A5 JP 2023537444 A JP2023537444 A JP 2023537444A JP 2023537444 A JP2023537444 A JP 2023537444A JP 2023539949 A5 JP2023539949 A5 JP 2023539949A5
Authority
JP
Japan
Prior art keywords
chemical compound
compound according
atom
group
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/051209 external-priority patent/WO2022047579A1/en
Publication of JP2023539949A publication Critical patent/JP2023539949A/ja
Publication of JP2023539949A5 publication Critical patent/JP2023539949A5/ja
Pending legal-status Critical Current

Links

JP2023537444A 2020-09-01 2021-09-01 ハロゲン化シロシビン誘導体および使用方法 Pending JP2023539949A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073104P 2020-09-01 2020-09-01
US63/073,104 2020-09-01
PCT/CA2021/051209 WO2022047579A1 (en) 2020-09-01 2021-09-01 Halogenated psilocybin derivatives and methods of using

Publications (2)

Publication Number Publication Date
JP2023539949A JP2023539949A (ja) 2023-09-20
JP2023539949A5 true JP2023539949A5 (cg-RX-API-DMAC10.html) 2024-09-09

Family

ID=80492287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537444A Pending JP2023539949A (ja) 2020-09-01 2021-09-01 ハロゲン化シロシビン誘導体および使用方法

Country Status (10)

Country Link
US (3) US11998557B2 (cg-RX-API-DMAC10.html)
EP (1) EP4208445A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023539949A (cg-RX-API-DMAC10.html)
KR (1) KR20230062595A (cg-RX-API-DMAC10.html)
CN (1) CN116348106A (cg-RX-API-DMAC10.html)
AU (1) AU2021337466A1 (cg-RX-API-DMAC10.html)
CA (1) CA3191102A1 (cg-RX-API-DMAC10.html)
IL (1) IL301026A (cg-RX-API-DMAC10.html)
MX (1) MX2023002557A (cg-RX-API-DMAC10.html)
WO (1) WO2022047579A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス, インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
KR20240017363A (ko) * 2021-06-02 2024-02-07 세인트 조셉스 유니버시티 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법
WO2023130075A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified organisms for producing psychotropic alkaloids
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024178504A1 (en) * 2023-02-27 2024-09-06 Enveric Biosciences Canada Inc. Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using
CN116904348B (zh) * 2023-06-15 2026-07-31 厦门大学 一种海洋链霉菌Streptomyces sp. P-10及其的应用
US12157722B1 (en) 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
CN121866243A (zh) * 2023-09-07 2026-04-14 耶路撒冷希伯来大学伊森姆研究发展有限公司 致幻化合物、其制备方法及其用途
GB202315025D0 (en) * 2023-09-29 2023-11-15 Psylink Uab Production and medical use of psilocybin and related compounds
WO2025073360A1 (en) 2023-10-04 2025-04-10 Enzyan Biocatalysis Gmbh Biocatalytic cascade for the production of tryptamine derivatives
WO2025189271A1 (en) * 2024-03-15 2025-09-18 Enveric Biosciences Canada Inc. N-heterocycle substituted tryptamine derivatives and methods of using

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
JPH09510216A (ja) * 1994-03-11 1997-10-14 イーライ・リリー・アンド・カンパニー 5−ht▲下2b▼受容体に関連する病態を治療するための方法
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
JP2003516749A (ja) * 1999-12-15 2003-05-20 シンジェンタ・パティシペーションズ・アクチェンゲゼルシャフト ハロゲン化反応のための組成物および方法
BR0312175A (pt) 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso
WO2004085392A1 (en) * 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
US20080171779A1 (en) * 2007-01-16 2008-07-17 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
EP2209380A4 (en) * 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
CN104276993B (zh) * 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
EP3519816A4 (en) * 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
WO2018106907A1 (en) * 2016-12-08 2018-06-14 Novatarg, Inc. Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary
US11723894B2 (en) 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
JP7093961B2 (ja) * 2018-02-13 2022-07-01 国立大学法人金沢大学 ストレス低減薬剤
JP2021514682A (ja) * 2018-03-08 2021-06-17 ニュー アトラス バイオテクノロジーズ エルエルシー トリプタミンの生産方法
FI129102B (en) * 2018-03-19 2021-07-15 Teknologian Tutkimuskeskus Vtt Oy Heterological production of psilosybin
US12616706B2 (en) * 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
EP3999182A1 (en) * 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
US20230021957A1 (en) * 2019-12-04 2023-01-26 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
EP4208457A1 (en) 2020-09-04 2023-07-12 Gilgamesh Pharmaceuticals, Inc. Azetidinyl tryptamines and methods of treating psychiatric disorders
KR20240017363A (ko) * 2021-06-02 2024-02-07 세인트 조셉스 유니버시티 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법

Similar Documents

Publication Publication Date Title
JP4301571B2 (ja) 改良された生物学的利用能を有する医薬のプロドラッグ
JP2020189864A5 (cg-RX-API-DMAC10.html)
JP2010525063A (ja) ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
JP2025524914A5 (cg-RX-API-DMAC10.html)
JPH10508858A (ja) 改良抗ウイルス性プロドラッグ
CA2409613A1 (en) Methods and compositions for treating hepatitis c virus
CN102906102A (zh) 含磷活性物的立体选择性合成
CN114366745A (zh) 治疗沙粒病毒科和冠状病毒科病毒感染的方法
JP2023543059A5 (cg-RX-API-DMAC10.html)
JPS6254118B2 (cg-RX-API-DMAC10.html)
JP2008523098A5 (cg-RX-API-DMAC10.html)
JP2010501584A5 (cg-RX-API-DMAC10.html)
EA007867B1 (ru) Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
JP2019515884A5 (cg-RX-API-DMAC10.html)
JP2023512557A5 (cg-RX-API-DMAC10.html)
JPH0259833B2 (cg-RX-API-DMAC10.html)
JP2021102643A5 (cg-RX-API-DMAC10.html)
CN100575335C (zh) 氨基-丙醇衍生物
JP2025507292A5 (cg-RX-API-DMAC10.html)
JP2024529476A5 (cg-RX-API-DMAC10.html)
CA3153281A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20130072530A1 (en) Novel ep4 agonist
JPH05509307A (ja) プリンの抗ウイルス性ホスホノ―アルケン誘導体
ES2488821T3 (es) Proceso de preparación de un compuesto antiviral
JP2006504673A5 (cg-RX-API-DMAC10.html)